Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications.
We've helped large and small companies and governments around with world with projects such as:
After years of maintaining DrugPatentWatch as a comprehesive analytics platform, we're making a distillation of cutting-edge information available to you as a daily newsletter.
DrugPatentWatch has been publishing critical business intelligence since 2002, so we've learned what matters to you.
We've served hundreds of clients in more than 70 countries, including from investment banks, big/small drug companies, payers, governments, and more…
It is from serving these diverse needs that the Daily Briefing was born.
The purpose of the Daily Briefing is to arm you with objective information so you can gain deep insights into gaps in the market and how they can be exploited tomorrow.
In addition to our daily updates of patent expirations and other market-changing events, the Daily Briefing includes articles on topics like:
We plan on charging $1,000 per year as we expand our team and invest more into the Daily Briefing.
But if you subscribe now you can lock in the introductory rate of $39/month.
And if you’re unhappy with the product, just tell us and we’ll refund you your money.